Edition:
United States

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

5.50USD
4:00pm EDT
Change (% chg)

$0.22 (+4.27%)
Prev Close
$5.28
Open
$5.25
Day's High
$5.55
Day's Low
$5.25
Volume
45,953
Avg. Vol
139,916
52-wk High
$8.55
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related... (more)

Overall

Beta: 3.53
Market Cap(Mil.): $326.01
Shares Outstanding(Mil.): 62.69
Dividend: --
Yield (%): --

Financials

  ADVM.OQ Industry Sector
P/E (TTM): -- 98.72 30.39
EPS (TTM): -1.02 -- --
ROI: -25.01 0.92 12.61
ROE: -25.59 -0.89 14.80

BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30

* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Adverum Biotechnologies Announces Leadership Changes

* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN

May 03 2018

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

May 01 2018

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 06 2018

Earnings vs. Estimates